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Objective: In this pilot study are presented the
first clinical experiences of the use of a resorbable
bioimplant made of esterified hyaluronic acid in-
serted in the microdissected superficial layer of the
lamina propria (SLLP), also called Reinke’s space, af-
ter a flap excision procedure for a benign vocal fold
lesion. Laryngeal and vocal evolution of implanted
patients are depicted and discussed. Study Design:
Eleven bio-implants have been inserted in microdis-
sected SLLP of 11 cases presenting with benign vocal
fold lesions. The surgical procedure consisted of the
excision of primary lesion by a microflap technique
immediately followed by implantation of esterified
hyaluronic acid in Reinke’s space. Methods: All pa-
tients underwent rigid laryngoscopy and a microsur-
gical procedure under general anesthesia. The cordal
lesion was treated with cold instrumentation of
Bouchayer (7 cases) or with a mixed technique using
CO2 laser (4 cases). After the classical freeing-up of
Reinke’s space and the creation of a mucosal flap, a
few fibers of esterified hyaluronic bioimplant are
gently arranged in Reinke’s space before redraping
the ligament and closing the cordal incision with a
few drops of fibrin glue. Laryngeal and vocal assess-
ments were performed pre- and postoperatively in all
patients using videostroboscopy aswell as perceptual
and objective voice evaluation. All patients were fol-
lowed in a longitudinalmanner: between two and five
postoperative evaluations were performed. The long-
est follow-up was 19 months and the shortest 2
months. Results: All cases exhibited postsurgical im-
provement of the pliability of the SLLP. None of them
developed an adverse scarring process. Improvement
of SLLP’s pliability was maintained in time in all
cases. Vocal improvement was observed in all. Tem-
porary inflammation was noted in one case. There
were no serious adverse effects apparent during the
follow-up period. Conclusion: Bio-implantation of es-
terified hyaluronic acid in Reinke’s space is techni-
cally easy and well tolerated. All treated cases exhib-
ited postoperative good pliability of the SLLP
compared with their preoperative evaluation. Key
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Normal human vocal folds (VF) have a very special-
ized and unique laminar histologic architecture. Under
the squamous epithelium lie the three layers of connective
tissue called the lamina propria (LP). Those layers have a
distinct structure and also different mechanical proper-
ties. The superficial layer of the lamina propria (SLLP),
also called Reinke’s space, is located just under the epi-
thelium. More deeply located, the intermediate layer rich
in elastic fibers and the deep layer rich in collagen fibers,
form together the vocal ligament. Under the LP lies the
thyroarytenoid muscle or vocal muscle.
In the body-cover model of vibration proposed by
Hirano,1 the cover is composed of the epithelium and the
SLLP. In this model, the natural pliability of the SLLP is
essential to normal voice production. The cellular compo-
sition of SLLP is very sparse, made of fibroblasts and
macrophages. Its “jelly like” structure is caused by a very
loose elastic and collagen fibrous scaffolding and by the
interstitium molecules of the extracellular matrix (ECM).
Among those molecules, hyaluronic acid or hyaluronan
(HA), a glycosaminoglycan, which is a normal constituent
of the ECM everywhere in the body, appears to play an
important role in determining the biological, mechanical,
and wound healing characteristics of the SLLP.2 HA is a
high molecular weight glycosaminoglycan first described
by Meyer and Palmer3 in 1934 who extracted the molecule
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from the vitreous humor of the eye. HA influences the
thickness of the LP: men possess a thicker LP compared
with women, and this could be caused by a three to four-
fold amount of HA in the men’s LP.4
HA not only influences thickness of SLLP but also its
visco-elastic characteristics: HA is necessary to maintain
both optimal viscosity and stiffness of SLLP. In 1999,
Gray et al.5 showed that the removal of HA from the SLLP
of two human cadavers increased the tissue viscosity by
two to fourfold. Stiffness of the SLLP is also influenced by
the amount of HA present, which in turn influences the
stability of the frequency of vibration: a less stiff SLLP
leads to a more unstable vibratory rate. In 2001, Chan et
al.6 demonstrated that removal of HA from the LP of five
adult male cadavers decreased the stiffness of the VF
cover by an average of 35% and increased dynamic viscos-
ity by 70%.
HA deeply influences cell behavior and appears to be
an important regulator of wound repair and of morphoge-
netic events. Previous studies have shown that HA influ-
ences collagen deposition and that high levels of HA re-
duce scar tissue formation with less fibrosis and less
contracture.7
The growing knowledge of the natural biomechanical
properties of the VF main vibrator, the mucosal cover, has
influenced the microsurgical procedures for the treatment
of benign VF lesions: restoration of mucosal vibratory
function is known to be the most important goal to achieve
to improve not only the quality of voice but the aerody-
namic effectiveness of the laryngeal vibrator and hence
the ease of phonation. Many authors have stressed the
importance of preserving as much SLLP as possible dur-
ing cordal microsurgery.8,9 When SLLP is damaged to a
sufficient extent, its molecular structure is modified: the
normal proteoglycans and glucosaminoglycans such as HA
are replaced by collagen fibers and fibronectin8,10 and scar
tissue is created, resulting in increased stiffness of the
mucosal cover and reduced mucosal motion during cordal
oscillation11 because of the change in the viscoelastic prop-
erties of the scarred mucosal cover.
In our personal experience, even extremely careful
VF microsurgery represents a potential risk of local adhe-
sion of the epithelial basal membrane to the ligament: in
case of wide dissection of the Reinke’s space (such as in
microsurgical treatment of Reinke’ s edema), in case of a
greater loss of tissue than expected inside the SLLP (such
as in microdissection of type III intracordal cysts),8 or
when the microsurgically treated pathology is primarily
characterized by an absence of normal SLLP (such as in
submucosal localized fibrosis or like in type II vergeture).
Knowing the favorable and important biological and
mechanical roles played by HA in normal SLLP, we have
been interested in using an HA-derivative bioimplant in
those surgical cases where a deeply damaged SLLP is
observed. The implant should be resorbable to play only a
temporary role: it should prevent the early adhesion of the
epithelial basement membrane to the underlying ligament
and if possible allow a better healing process of the SLLP.
Many exogenous HA preparations are commercially
available and have been proven to be nontoxic and non-
antigenic because of the absence of proteins, as well as
perfectly biocompatible. They have been used extensively,
for many years, in many surgical specialties such as oph-
thalmic, gynecologic, abdominopelvic, plastic, and osteo-
arthritic surgery.12 The objectives of the current prospec-
tive study are to evaluate the laryngeal function and vocal
results obtained after implantation of a modified HA bio-
implant, esterified hyaluronic acid (EHA), under the mu-




Eleven patients (3 men and 8 women) who underwent a
microsurgical procedure on their vocal cords were selected for
treatment between February 14, 2003 and October 1, 2004. All of
them presented with benign lesions of the VFs and underwent a
microsurgical procedure and implantation of EHA in Reinke’s
space. Diagnosis, sex, age, surgical technique (with or without
laser), and personal characteristics are depicted in Table I. Two
cases benefited from a bilateral procedure, but only one side was
implanted.
Procedure
All patients underwent general anesthesia and routine la-
ryngeal intubation (tracheal tube size: 5.5–6.5). A direct laryn-
goscopy was performed in all patients (Kleinsasser type laryngo-
scope, Storz 8590C and 8590B). The microsurgical procedure was
done under 25 magnification (Microscope Leica M655). The
cordal lesion was treated either with cold instrumentation of
Bouchayer only (Microfrance) or with CO2 Laser (Sharplan 40C).
The surgical procedure accomplished the classical liberation of
Reinke’s space and the creation of a mucosal flap to redrape the
cordal ligament. For the patients with Reinke’s edema, after
suctioning of the submucosal edema, care was taken not to sac-
rifice too large an amount of mucosa to be able to close the
incision without any superficial defect.
The decision to use a bioimplant made of EHA was taken at
the time of the surgical procedure and was linked to an estimated
higher surgical damage to the SLLP. A few fibers of EHA bioim-
plant are taken with the microforceps and gently arranged in
Reinke’s space between the ligament and the mucosal flap. The
cordal mucosal flap is then precisely closed above the implant and
maintained in place by using two or three drops of Fibrin glue
(Tissucol DUO 500°, 0,5 mL Baxter, Deerfield, Il). Surgical pho-
tographs of the procedure performed in case 11 suffering of left
VF mucous cyst are presented in Figure 1.
Postoperatively, all patients were advised to adhere to a
vocal rest for 8 days. Peroperatively, they received a 125 mg
intravenous injection of methylprednisolone. Medical postopera-
tive treatment consisted of degressive oral methylprednisolone,
clobutinol hydrochloride, paracetamol, and amoxyclavulanate for
1 week.
Bioimplant
The commercially available EHA presents as a fiber mate-
rial made of HYAFF (Fidia Advanced Biopolymers, Abano,
Terme, Italy). The HYAFF polymers are modified HA derived by
esterification of the carboxyl group of the glucuronic acid moiety
of the polymer with linear or aromatic alcohols. The EHA implant
used in this study is HYAFF 11 (MeroGel), in which 100% of
carboxyl groups of HA are esterified with benzyl alcohol and is a
registered trade mark of Medtronic Xomed, Jacksonville, FL.
When placed in contact with the human body fluids, the
fiber-like material transforms itself into a highly hydrated gel,
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which is then totally degradable through hydrolysis of the ester
bond, releasing free alcohol and HA. The two molecules are then
metabolized in the body through their normal metabolic degra-
dation pathways.13
Laryngoscopic Examination
All patients underwent a general ear, nose, and throat clin-
ical examination. Videolaryngostroboscopy was performed preop-
eratively and postoperatively. We used a Wolff rigid 70° endo-
scope 4450.47 connected to a Wolff laryngostroboscope 5052. All
patients were videotaped on an Olympus camera Visera OTV-
57.Videotapes of each patient were acquired using a video re-
corder PanasonicAG-5700. Video printouts of a Sony UP-3000P
video printer were conserved for data files. Topical anesthesia of
the pharynx (xylocaı¨ne 10% spray) was used. The patients were
asked to sustain an /e / at different pitches.
Amplitude of vibration and of mucosal wave as well as
symmetry, inflammation, presence of a glottic gap, and of VF
deformation are the videostroboscopic findings that were taken
into account. Amplitude of vibration, mucosal wave and glottic
gap were evaluated on an analogic scale.
For amplitude vibration and mucosal wave, we used a 10 cm
scale. Amplitude of vibration is considered normal if noted at 5,
increased if above 5, and decreased below 5.
Mucosal wave is considered normal if noted at 10. Every
value between 10 and 0 is considered a decreased wave. A wave
noted 0 is a completely absent wave.
For glottic closure, a scale of 5 cm is used. Glottic closure is
considered complete at 5 and diminished if noted between 0 and
5.
Voice Evaluation
The voices were recorded in a soundproof booth on a Kay
Elemetrics Computerized Speech Lab with a Kay Elemetrics
head-mounted microphone. The distance between the mouth and
the microphone was approximately 3 cm. Three sustained vowels
/a/ and five standardized texts for French were recorded at each
visit. We used the GRBASI scale for the subjective evaluation of
the patient’s voice quality, after listening to the five productions
of the standardized texts: G(rade), R(oughness), B(reathiness),
A(sthenia), S(train), I (nstability). Each item is quoted as 0 (nor-
mal), 1 (light), 2 (moderate), and 3 (severe).
Software from Kay Elemetrics, Multi-Dimensional Voice
Program (MDVP) was used to obtain voice quality objective data.
Measurements of average fundamental frequency (average Fo), of
highest and lowest fundamental frequency (Fhi, Flo), SD of Fo
(STD), phonatory Fo range (PFR), jitter ratio (Jitt), and noise-to-
harmonic ratio (NHR), were derived from 3 second segments of
each of the sustained /a/. For patient 3, the preoperative objective
voice evaluation was obtained from the CSL Main Program Soft-
ware because intensity of voice was too low to permit the use of
MDVP Software.
RESULTS
All the results obtained can be organized in accor-
dance with the time spent after surgery:
1. Early postoperative evaluation (EPOE): between 1 and
2 weeks after surgery.
Fig. 1. Surgical photographs of case 11’s procedure (left vocal fold
[VF] mucous cyst). (1) Preoperative microlaryngoscopic view of left
VF mucous cyst. (2) Opening of the Reinke’s space. (3) Presentation
of MeroGel fibers before insertion in the microdissected superficial













Case 1 M Right submucosal fibrosis Yes No 51 X Right No
Case 2 M Right intracordal open cyst No Stopped
(in 1994)
74 X Right No
Case 3 F Right intracordal organized hematoma No No 47 X Right No
Case 4 F Bilateral Reinke’s edema No Yes 68 X Left Yes
Case 5 F Bilateral Reinke’s edema, left open cyst,
and localized vergeture
No Yes 44 X Left Yes
Case 6 F Right intracordal open cyst, bilateral
hypotony
Yes No 27 X Right No
Case 7 F Bilateral Reinke’s edema No Yes 70 X Left Yes
Case 8 F Right Reinke’s edema No Stopped 44 X Right Yes
Case 9 F Left cordal vergeture No No 35 X Left No
Case 10 M Left cordal vergeture, right sulcus No No 12 X Left No
Case 11 F Left mucous cyst Yes No 55 X Left No
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2. Intermediate postoperative evaluation (IPOE): be-
tween 3 and 4 weeks after surgery.
3. Late postoperative evaluation (LPOE): between 7 and
12 weeks after surgery.
4. Long-term postoperative evaluation (LTPOE): between
15 and 38 weeks after surgery.
5. Very long-term postoperative evaluation (VLTPOE):
available in 3 cases, between 10 and 19 months.
Preoperative values for case 7 are obtained after her
first microsurgery on the right VF (cure of a huge Reinke’s
edema) with no bioimplantation realized on that right VF.
No serious adverse effect was noted during the observa-
tion period.
Laryngoscopic Examination
Figure 2 shows the videostroboscopic findings of the
11 cases in three separate graphs.
Inflammation. Only case 7 suffered from a signifi-
cant inflammation after treatment: the VF appeared de-
prived of any vibratory movement or mucosal wave at
EPOE. Voice rest for 2 weeks and a medical treatment
consisting of methylprednisolone and ultrasonic humidi-
fying solution (propylene glycol 5% in a physiologically
balanced salt solution) permitted the patient to regain an
almost normal wave at IPOE
Vocal fold general aspect. Concerning the general
appearance of the treated VF observed at the EPOE, all of
them except case 7 already exhibited a noninflammatory,
smooth, well-hydrated, good looking aspect at rest. This was
particularly striking in the two worst cases: case 3 suffering
from an intracordal organized hematoma and case 10 suffer-
ing from an extremely deep and long vergeture.
A slight convexity of the implanted VF was visible at
EPOE in case 1, 2, and 10 but rapidly disappeared and
was no longer visible at IPOE. Case 3 still exhibited a very
slight deformation of the free margin of the treated VF at
LPOE. In case 11, who was suffering from an anterior left
mucous cyst, comparison of the general aspect of the
treated VF at EPOE and LPOE shows a change in the
color of the surgical zone together with a straighter upper
lip of the VF.
Amplitude of vibration. Amplitude of vibration in-
creased after bio-implantation in all of the eight cases who
had a decreased preoperative amplitude. We lack EPOE
for case 4, whereas case 9 exhibited extreme tension and
vocal inhibition, which lead to the impossibility to obtain
normal vibration and stroboscopic assessment. The 3
cases who experienced a decreasing amplitude after sur-
gery had a preoperative increased vibratory amplitude
(cases 5, 7, and 8).
Mucosal wave. Preoperatively, a mucosal wave was
absent or decreased in 8 of 11 cases (cases 1, 2, 3, 5, 6, 9,
10, 11) and normal in 3 of 11 cases (cases 4, 7, and 8). The
cases with a normal preoperative mucosal wave were
those with Reinke’s edema. All cases with a decreased
wave experienced an increasing mucosal wave after mi-
crosurgery and bio-implantation. Case 7, who suffered
from a significant inflammatory response at the early
postsurgical check up, with no mucosal wave visible at the
time, regained an almost normal wave at the IPOE.
Glottic closure. Glottic closure improved in 6 of 11
cases (cases 1, 4, 7, 9, 10, 11), was unchanged in 2 cases
(cases 3 and 5), and was slightly diminished after surgery
in 3 cases of 11 (cases 2, 6, 8).
Fig. 2. Videostroboscopic data. (A) Amplitude of vibration. (B) Am-
plitude of mucosal wave. (C) Glottic closure. PREO  preoperative
evaluation; EPOE  early postoperative evaluation; IPOE  inter-
mediate postoperative evaluation; LPOE  late postoperative eval-
uation; LTPOE  long-term postoperative evaluation; VLTPOE 
very long-term postoperative evaluation.
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Voice Evaluation
Perceptual voice evaluation. Table II depicts the
perceptual voice evaluation of the cases according to the
time of surgery.
All our cases experienced a progressive improvement
of voice with the passage of time after the microsurgical
procedure. A grade 1 dysphonia was achieved by 6 of 11
cases in a period of time ranging from 1 to 12 weeks. The
worst result was observed in case 10 and case 5, who still
exhibit a grade 3 dysphonia at LTPOE and LPOE, respec-
tively.
Objective voice quality data. Objective voice qual-
ity data are presented in Figure 3. The values are the
mean of the values obtained from the three consecutive
sustained /a/ measured on the MDVP software.
STD and PFR show a degressive pattern after micro-
surgery and bio-implantation in 9 cases /11 cases (cases 1,
2, 3, 4, 6, 7, 8, 9, 11). Case 5 is the only patient exhibiting
an increase in the value of STD and PFR. Case 10 exhibits
very fluctuant values.
Considering LPOE and LTPOE, Jitt diminished in
six cases (cases 2, 3, 7, 8, 9, 11), increased in two cases
(cases 5 and 6), and was almost unchanged in two cases
(cases 1, 4, and 10).
NHR shows a decreased pattern after microsurgery
and bio-implantation in 8 cases of 11 (cases 1, 2, 3, 4, 5, 7,
8, 9) and an increase in 2 cases (cases 6 and 10) at the
LTPOE. NHR is almost unchanged in case 11, after an
initial drop of its value. The best result was obtained in
patient 3.
DISCUSSION
The objective of this pilot study is to evaluate the
laryngeal function and vocal results obtained after inser-
tion of a resorbable EHA implant under the mucosal flap,
in the Reinke’s space, at the end of a microsurgical proce-
dure for benign cordal lesions. The decision of using the
implant was in all cases guided by the estimated risk of a
too important damage to the SLLP, primary or postsurgi-
cal, which could preclude favorable postsurgical vibratory
evolution. Because of the small size of this series and the
inhomogeneous nature of the treated pathologies, evalua-
tion of the results obtained will be performed in a longi-
tudinal perspective.
All the observed cases showed an early excellent gen-
eral aspect of the treated VF, except case 7, who experi-
enced inflammation. All cases showed an excellent post-
operative mucosal wave and vibratory amplitude. In all
observed cases, mucosal wave improvement had reached
its maximum rating at LPOE or LTPOE, whereas early
improvement was already seen in six cases.
Case 4, who underwent bilateral microsurgical treat-
ment for a severe Reinke’s edema, exhibited a better am-
plitude of vibration on the bioimplanted side compared
with the side that was not implanted. Unilateral insertion
of EHA was realized on one side because one mucosal flap
was tighter, and we were concerned with the risk of ex-
trusion of the bioimplanted material on that side.
Bioimplantation is Well Tolerated, the General
Aspect of Treated VF Being Excellent;
Inflammation has been Observed in Only Case 7
In this particular case, we believe that the use of the
CO2 laser combined with an initially too lateral mucosal
incision with exposition of the vocal ligament probably
played the major role in the development of a considerable
inflammatory response. The appearance of the VF was
similar to inflammatory responses observed in our expe-
rience after laser cordectomies type I.
Time Evolution of Laryngeal Images Shows
Excellent Early but also Long-Term Tolerance of
EHA Bioimplant
The VLTPOE available in three cases (1, 2, and 4)
shows an excellent stability of the laryngeal image with a
slight continued increase of the amplitude of movement in
case 2 and 4, who are finally rated as having a lateral
movement of vibration slightly above the normal ampli-
tude. Case 4 also reached complete glottic closure at that
very long-term evaluation. No adverse local reactions such
as granuloma or stiffness have been observed in any of our
cases.
TABLE II.
Perceptual Voice Evaluation: GRBASI Scale.
Preoperative Evaluation EPOE IPOE LPOE LTPOE VLTPOE
Case 1 220023 110011 110000 110000 110011 111001 (16 months)
Case 2 220022 221010 – 110011 110011 110011 (19 months)
Case 3 331033 121012 212112 111022 000001
Case 4 331033 – 211103 111001 – 000000 (10 months)
Case 5 331013 – 111001 – 320011
Case 6 231013 110102 – 111112 –
Case 7 330002 332303 111001 110001 110001
Case 8 320011 211011 – 221001
Case 9 333033 3—3– – 211032 111121
Case 10 333033 321223 222132 323233
Case 11 333033 111131 – 111101
GRABASI grade, roughness, breathiness, asthenia, strain, instability; EPOE  early postoperative evaluation; IPOE  intermediate postoperative
evaluation; LPOE  late postoperative evaluation; LTPOE  long-term postoperative evaluation; VLTPOE  very long-term postoperative evaluation.
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In the field of laryngology, previous animal studies
investigated the fate of modified HA injected in the VFs of
an animal model: dextranomeres in hyaluronic (DiHa) and
hylan B gel, a crossed-linked HA (Hylaform, Biomatrix
Inc., Ridgefield, NJ,) injected in rabbit VFs were shown to
be nontoxic and free of allergic as well as foreign body
reactions.14,15 Hylan B gel, largely used in the treatment
of wrinkles, did not induce any inflammatory reaction
when injected in the rabbit VF. Those HA derivatives have
then been used in augmentative surgery as injectable
materials in patients suffering of glottic insufficiency,
with very good results on videostroboscopic parame-
ters.16,17 In the case of hylan B gel, the authors noted a few
patients with early signs of inflammation (within a week
after injection), but all cases resolved without sequelae
within 30 days.
The biopolymer used in this study (MeroGel) and the
Hylan B gel (Hylaform) are both obtained from rooster
combs, but modification of the molecule of HA is different:
esterification in the first case and cross-linking in the
second case. Hylaform presents as an injectable gel,
whereas MeroGel is a solid, fiber material. The site of
bioimplantation in the present study is the microdissected
SLLP and not the muscle vocalis or the vocal ligament
such as in previous clinical studies. It is the first time that
exogenous HA has been placed extremely superficially in
the human VF, immediately under the mucosal flap, and
in this aspect, the fiber presentation of the EHA implant is
important because it allows us to arrange it precisely
before closure of the mucosal flap. The goal is also very
different: we plan on a temporary action and not on a
long-term residence of the HA implant in the treated VF,
explaining our choice for a resorbable implant, whereas
previous studies are planning on persistence of implanted
modified HA.
One question raised by these clinical observations is
of course the estimated time of residence of the EHA
implant in the Reinke’s space. According to the manufac-
turer of MeroGel, the implant dissolves in 2 weeks in the
nose and in 6 weeks in the ear. From the observation of the
laryngeal image, we interpret the disappearance of a
slight convexity of the treated VF observed in three of our
Fig. 3. Objective voice data. (A) Av-
erage fundamental frequency (Fo).
(B) Standard deviation of Fo (STD). (C)
Phonatory fundamental frequency
range (PFR). (D) Jitter ratio. (E) Noise-
to-harmonic ratio (NHR). PREO pre-
operative evaluation; EPOE  early
postoperative evaluation; IPOE  in-
termediate postoperative evaluation;
LPOE  late postoperative evaluation;
LTPOE  long-term postoperative
evaluation; VLTPOE  very long-term
postoperative evaluation.
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cases as the probable resorption of the inserted EHA im-
plant: this would mean that 3 to 4 weeks are necessary for
the resorption of the implant. The estimated time of res-
idence of EHA used in this study is far enough for the goal
pursued: creation of a temporary physical barrier between
epithelial basement membrane and the VF ligament and
creation of optimal conditions for the healing process in-
side the SLLP. Several recent animal studies show that
levels of HA are decreased in injured VF in the early days
after injury.18,19 The authors believe that low HA level
produces a less than optimal environment for normal tis-
sue regeneration and may contribute to formation of scar
tissue. They state that those studies could provide a ra-
tionale reason to increase HA in acute VF scar to improve
postoperative vocal outcomes.
Perceptual Voice Evaluation Shows Good Voice
Recovery after Microsurgery and
Bioimplantation
Laryngeal pathologies are usually associated with an
elevation of the value of Jitt, STD, PFR, and NHR. Vocal
improvement is therefore linked to a postoperative lower-
ing of their value. Lowering of STD, PFR, and NHR shows
objective vocal evolution that can be interpreted as vocal
improvement in 9 cases of 11 for STD, PFR, and NHR. Jitt
values exhibit less favorable vocal evolution in our series.
From the results obtained in our series of 11 consec-
utive EHA bio-implants, we can conclude that the EHA
implant is safe and well tolerated in the micro dissected
SLLP. We observed good to excellent pliability of the VF
cover after treatment, especially in very bad cases such as
huge organized hematoma, deep intracordal cysts, and
extremely deep vergeture. Those results are encouraging
and could be linked to a temporary raise of the level of HA
thanks to the insertion of exogenous modified HA, which
eventually favors an optimal healing and reconstitution of
a new SLLP in the treated VF. Of course, the small size of
this series and the absence of control cases forbid us to
conclude to an improvement of SLLP’s pliability because
of the use of such an implant. Nevertheless, the use of
such an implant easy to arrange under the mucosal flap,
because of its fiber structure, could be an important help
in the treatment or the prevention of cordal scars. The
implant would cushion the dissected scarred mucosa and
maybe favor regeneration of a thicker and more pliable
SLLP. Previous studies evaluating viscoelastic shear
properties of various implantable biomaterials already
stressed that biomechanically speaking, HA could be a
potentially optimal bio-implant for the surgical manage-
ment of VF mucosa defects and LP deficiencies.17,20,21
CONCLUSION
In this pilot study, the use of exogenous modified HA
in the microdissected SLLP of 11 consecutive cases treated
for benign VF lesions showed no adverse reaction during
the time of follow-up (between 8 weeks and 19 months).
Excellent pliability of the mucosal cover was obtained
postoperatively, particularly in cases where mucosal stiff-
ness was extremely important preoperatively.
These good results obtained in these first clinical
experiences have to be confirmed by larger series and
long-term follow-up in the latest treated cases. Controlled
studies are necessary in the future to evaluate the role of
implantation of modified HA in microdissected SLLP on
the phonatory and mucosal pliability outcomes.
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